On April 7, 2005, the FDA required Pfizer to remove Bextra from the U.S. market. Bextra (also known as valdecoxib) is a member of the category of drugs called "Cox-2 Inhibitors." It was also used to provide pain relief and anti-inflammatory effects for arthritis sufferers. After considering the findings of the FDA Advisory Committee, which met in February of 2005, the FDA determined that Bextra's "overall risks versus benefit profile" is unfavorable.

Studies released as recently as December of 2004, show a very high correlation between Bextra use and serious cardiovascular events such as heart attack and stroke. This risk is especially high in those individuals who used the drug after having coronary artery bypass surgery. Bextra has also been strongly linked with a rare but deadly skin disorder called Stevens Johnson Syndrome (SJS).

If you or someone you know experienced a heart attack, stroke, or developed Stevens Johnson Syndrome while using Bextra, contact us online or call us toll free at 1-800-320-2384 to discuss your legal rights.